These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21380780)

  • 1. Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review.
    Kaidar-Person O; Billan S; Kuten A
    Med Oncol; 2012 Jun; 29(2):704-6. PubMed ID: 21380780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas.
    Park JC; Ma TM; Rooper L; Hembrough T; Foss RD; Schmitt NC; Sawhney R; Flanders A; Kang H
    Head Neck; 2018 Dec; 40(12):E100-E106. PubMed ID: 30478962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab for the treatment of salivary duct carcinoma.
    Limaye SA; Posner MR; Krane JF; Fonfria M; Lorch JH; Dillon DA; Shreenivas AV; Tishler RB; Haddad RI
    Oncologist; 2013; 18(3):294-300. PubMed ID: 23429737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy.
    Nabili V; Tan JW; Bhuta S; Sercarz JA; Head CS
    Head Neck; 2007 Oct; 29(10):907-12. PubMed ID: 17563907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of metastatic salivary duct carcinoma successfully treated with trastuzumab-based targeted therapy].
    Iguchi F; Taniguchi Z; Kusano J; Takahashi Y; Murai N
    Nihon Jibiinkoka Gakkai Kaiho; 2014 Aug; 117(8):1108-14. PubMed ID: 25255650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy.
    Prat A; Parera M; Reyes V; Peralta S; Cedrés S; Andreu J; Huguet P; del Campo JM
    Head Neck; 2008 May; 30(5):680-3. PubMed ID: 17972317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma.
    Jeong ISD; Moyers J; Thung I; Thinn MM
    Am J Case Rep; 2020 Jun; 21():e925181. PubMed ID: 32601266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.
    Thorpe LM; Schrock AB; Erlich RL; Miller VA; Knost J; Le-Lindqwister N; Jujjavarapu S; Ali SM; Liu JJ
    Head Neck; 2017 Mar; 39(3):E40-E44. PubMed ID: 28006087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
    Falchook GS; Lippman SM; Bastida CC; Kurzrock R
    Head Neck; 2014 Mar; 36(3):E25-7. PubMed ID: 23852769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carboplatin and Docetaxel in Patients With Salivary Gland Carcinoma: A Retrospective Study.
    Okada T; Saotome T; Nagao T; Masubuchi T; Fushimi C; Matsuki T; Takahashi H; Miura K; Tsukahara K; Tada Y
    In Vivo; 2019; 33(3):843-853. PubMed ID: 31028207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of trastuzumab in the management of salivary ductal carcinomas.
    Perissinotti AJ; Lee Pierce M; Pace MB; El-Naggar A; Kies MS; Kupferman M
    Anticancer Res; 2013 Jun; 33(6):2587-91. PubMed ID: 23749912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma.
    Takahashi H; Tada Y; Saotome T; Akazawa K; Ojiri H; Fushimi C; Masubuchi T; Matsuki T; Tani K; Osamura RY; Hirai H; Yamada S; Kawakita D; Miura K; Kamata SE; Nagao T
    J Clin Oncol; 2019 Jan; 37(2):125-134. PubMed ID: 30452336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report: ado-trastuzumab as second-line treatment in HER2 positive salivary duct carcinoma.
    Taha T; Billan S
    Anticancer Drugs; 2022 Jan; 33(1):e760-e763. PubMed ID: 34387606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term survival of a breast cancer patient with liver metastasis treated with trastuzumab and Paclitaxel].
    Ota Y; Ishikawa T; Yamada A; Shimizu D; Hasegawa S; Chishima T; Endo I
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):1091-4. PubMed ID: 20567114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study.
    Tőkés T; Szentmártoni G; Torgyík L; Kajáry K; Lengyel Z; Györke T; Molnár BÁ; Tőkés AM; Kulka J; Dank M
    Croat Med J; 2015 Apr; 56(2):128-38. PubMed ID: 25891872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of HER2/estrogen receptor cross-talk, probable relation to prolonged remission of stage IV breast cancer: a case report.
    Tisman G
    Tumori; 2009; 95(6):804-7. PubMed ID: 20210247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salivary duct carcinoma--a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression.
    Skálová A; Stárek ; Kucerová V; Szépe P; Plank L
    Pathol Res Pract; 2001; 197(9):621-6. PubMed ID: 11569926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
    Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Tada Y; Verhaegh GW; Schalken JA; Driessen CML; van Herpen CML
    Cancer Treat Rev; 2020 Sep; 89():102069. PubMed ID: 32717621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment.
    Hayashi H; Kimura M; Yoshimoto N; Tsuzuki M; Tsunoda N; Fujita T; Yamashita T; Iwata H
    Breast Cancer; 2009; 16(2):136-40. PubMed ID: 18548321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment.
    Shigematsu H; Nakamura Y; Tanaka K; Shiotani S; Koga C; Kawaguchi H; Nishimura S; Taguchi K; Nishiyama K; Ohno S
    Int J Clin Oncol; 2010 Dec; 15(6):615-20. PubMed ID: 20473628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.